Idera Bolsters Rare Disease Portfolio with Aceragen Buyout

Two rare disease companies - Idera Pharmaceuticals and Aceragen - are merging to pursue the common goal of an FDA approval that could come as early as 2024.

Related Keywords

Milano ,Lombardia ,Italy ,Philadelphia ,Pennsylvania ,United States ,John Taylor ,Carl Kraus ,John Kirby ,Daniel Salain ,Us Defense Threat Reduction Agency ,Idera Pharmaceuticals ,Fast Track ,Qualified Infectious Disease Product ,Threat Reduction Agency ,Chief Medical Officer Carl Kraus ,Chief Operating Officer Daniel ,General Counsel Bryant Lim ,Chief Financial Officer John Kirby ,Novaquest The Durham ,Resume ,Careers ,Dera Bolsters Rare Disease Portfolio With Aceragen Buyout ,Iospace ,Advice ,